Cyclic HDAC Inhibitors for Solid Tumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors show limited efficacy in treating solid tumors, such as breast cancer, renal cancer, and prostate cancer, restricting their widespread application in clinical practice.
Innovation Solution
Development of novel HDAC inhibitors with a specific structure, including a zinc binding group, linker, and cap group, featuring a five-membered ring formed by cyclization of an amide bond and connect unit, to enhance efficacy against solid tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HDAC inhibitors with simple sp2 hybrid connect units (amide and carbonyl) are used, then the molecular structure is simple and easy to manufacture, but the therapeutic efficacy on solid tumors is poor
Solution Approach 1:
The patent changes the hybridization state of the connect unit from sp2 (simple amide/carbonyl) to sp3 (cyclic structures with saturated carbons). This parameter change in molecular geometry and conformational flexibility leads to improved therapeutic efficacy against solid tumors while maintaining reasonable structural complexity through the use of cyclic frameworks.
Solution Approach 2:
The patent combines multiple structural components (ZBG, linker, CU with sp3 hybridization, and cap group) into a composite molecular architecture. The cyclic connect unit acts as a structural bridge that integrates the zinc-binding functionality with the cap group, creating a composite structure that achieves superior anti-tumor activity compared to simple linear amide structures.
2Reliability
If novel HDAC inhibitors with five-membered ring structure are developed, then the anti-tumor activity against solid tumors is significantly improved, but the synthesis complexity increases
Solution Approach 1:
The patent divides the HDAC inhibitor into four distinct functional segments: zinc binding group (ZBG), linker, connect unit (CU) with five-membered ring, and cap group. This segmentation allows each component to be optimized and synthesized separately, then assembled into the final active molecule, thereby managing synthesis complexity while achieving the desired anti-tumor activity.
Solution Approach 2:
The patent employs sp3 hybridized cyclic connect units with specific ring sizes (five-membered rings) and varying substituent parameters (R1-R6 groups). By systematically varying these structural parameters while maintaining the core cyclic architecture, the patent achieves improved anti-tumor efficacy through a series of related compounds with manageable synthetic complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new HDAC inhibitors exhibit excellent inhibitory activity against HDACs and demonstrate significant in vitro anti-tumor activity, providing a new approach for treating solid tumors.
Implementation Method 1
an HDAC small molecule inhibitor mainly consists of four components, including a zinc binding group (ZBG), a linker, a connect unit (CU) and a cap group
Data Source
AI summary
The present invention relates to a histone deacetylase inhibitor and uses thereof, belonging to the field of medicinal chemistry. The present invention prepares a class of HDAC inhibitors with a novel structure and high efficiency by introducing a succinimide fragment. The present invention has the beneficial effects of excellent inhibitory activity against HDACs and excellent in vitro anti-tumor activity, providing a new approach for the application of HDAC inhibitors in solid tumors and/or the treatment of diseases associated with uncontrolled histone deacetylase activity.